Canada Patient Derived Xenografts/PDX Models Market (2025-2030)
The Canada Patient Derived Xenografts/PDX Models Market was valued at $27.1 Million in 2025 and projected to reach to $38.6 Million by 2030, representing a compound annual growth rate of 7.3%. Canada's PDX Models market is positioned for steady growth as the country's healthcare system prioritizes personalized medicine and precision oncology.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Canada Patient Derived Xenografts/PDX Models Market Trends and Insights
- Canada's healthcare sector is increasingly adopting PDX models as a critical tool for personalized medicine and oncology research, driven by investments in precision therapeutics and academic research institutions.
- The Canadian market benefits from strong regulatory frameworks, collaborative research ecosystems, and growing pharmaceutical partnerships focused on drug development and validation. In Canada, the PDX models market is supported by leading research centers and biopharmaceutical companies seeking advanced preclinical testing platforms.
- Canada's commitment to healthcare innovation and cancer research has positioned the country as a key player in the North American PDX landscape.
- Between 2025 and 2030, Canada is anticipated to see accelerated adoption across academic medical centers, contract research organizations, and pharmaceutical firms developing targeted therapies..
Key Market Statistics
- CAGR (2025-2030) 7.3% CAGR
- Market Size, 2025 ~USD 27.1 Million
- Forecast, 2030 ~USD 38.6 Million
- Country Canada
Canada Patient Derived Xenografts/PDX Models Market Overview
Market Valuation :
Canada's PDX Models market is valued at $27.1 million in 2025, with projected growth to $38.6 million by 2030, reflecting strong adoption in precision oncology research.
Academic Research Leadership :
Canadian research institutions are increasingly leveraging PDX models for personalized medicine development, supported by government funding and collaborative research initiatives across major medical centers.
Precision Therapeutics Investment :
Canada's healthcare sector is investing significantly in precision therapeutics infrastructure, driving demand for PDX models as essential tools for drug development and patient-specific treatment validation.
Regulatory Support :
Health Canada's supportive regulatory framework for personalized medicine and advanced research models is facilitating increased adoption of PDX technologies among pharmaceutical and biotech companies.
Canada Patient Derived Xenografts/PDX Models Market Dynamics
- The 7.3% CAGR reflects increasing investments from academic institutions, government research funding, and pharmaceutical companies establishing Canadian operations.
- Major research hubs in Toronto, Vancouver, and Montreal are driving innovation in PDX technology applications. The market outlook remains positive through 2030, supported by Canada's strong life sciences ecosystem, collaborative research networks, and commitment to advancing cancer treatment methodologies.
- Continued partnerships between academic centers and industry players, combined with growing recognition of PDX models' value in reducing drug development timelines and improving therapeutic outcomes, will sustain market expansion..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Canada's PDX models market is valued at $27.1 million in 2025 and projected to reach $38.6 million by 2030, growing at a 7.3% CAGR.
- Canada's strong academic research infrastructure and pharmaceutical partnerships are driving adoption of PDX models for personalized oncology and drug development.
- Canada's regulatory environment and healthcare innovation focus support the expansion of preclinical testing platforms and contract research services.
- Between 2025 and 2030, Canada is expected to see increased investment in PDX technology from both domestic and international biopharmaceutical companies.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Canada Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODELS MARKET, BY END USER, 2023–2030
| Segment | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| ACADEMIC & RESEARCH INSTITUTES | 6.2 | 6.6 | 7.1 | 7.7 | 8.2 | 8.8 | 9.3 | 9.9 | 6.9 |
| CROS & CDMOS | 4.1 | 4.4 | 4.7 | 5 | 5.3 | 5.7 | 6 | 6.4 | 6.4 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 13.1 | 14.1 | 15.3 | 16.6 | 18 | 19.3 | 20.8 | 22.3 | 7.8 |
| TOTAL | 23.4 | 25.1 | 27.1 | 29.3 | 31.5 | 33.7 | 36.1 | 38.6 | 7.3 |
Target Audience
- Pharmaceutical & Biotech Companies : Canadian and international pharma firms need market data to evaluate PDX adoption rates, identify partnership opportunities with Canadian research institutions, and plan R&D investments in precision oncology.
- Academic & Research Institutions : Canadian universities and medical centers require market insights to benchmark their PDX capabilities, secure funding, and understand competitive positioning within Canada's precision medicine ecosystem.
- Healthcare Investors & Venture Capital : Investment firms targeting Canada's life sciences sector need market sizing and growth projections to identify promising PDX technology companies, research partnerships, and emerging opportunities.
- Medical Device & Service Providers : Companies offering PDX-related services, platforms, or technologies need Canadian market data to assess demand, identify customer segments, and develop localized commercialization strategies.
- Government & Policy Makers : Canadian health authorities and policy organizations require market intelligence to inform precision medicine initiatives, research funding priorities, and regulatory frameworks supporting PDX adoption.
Key Companies in the Canada Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Reasons to Buy this Report
- Market-Specific Sizing & Forecasts : Access precise valuation data for Canada's PDX market ($27.1M in 2025) with detailed 5-year forecasts, enabling accurate budget allocation and investment planning specific to the Canadian market.
- Regional Growth Drivers Analysis : Understand Canada-specific factors driving 7.3% CAGR, including academic research investments, government funding mechanisms, and regulatory support that differentiate this market from global trends.
- Competitive Landscape Intelligence : Identify key Canadian research institutions, pharmaceutical players, and biotech companies adopting PDX models, with insights into partnership opportunities and market positioning strategies.
- Strategic Market Entry Guidance : Develop informed go-to-market strategies for Canada with localized insights on healthcare infrastructure, reimbursement pathways, and collaboration models with Canadian academic and clinical centers.
- Investment & Expansion Planning : Support capital allocation decisions and expansion plans with Canada-focused market intelligence, identifying high-growth segments and emerging opportunities in precision therapeutics and oncology research.
Frequently asked questions
What is the current market size of PDX models in Canada?
Canada's Patient Derived Xenografts market is valued at $27.1 million in 2025 and is projected to grow to $38.6 million by 2030.
What is the growth rate of the PDX models market in Canada?
Canada's PDX models market is expected to grow at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2030.
What factors are driving PDX model adoption in Canada?
Canada's PDX market growth is driven by strong academic research institutions, pharmaceutical partnerships, precision medicine initiatives, and regulatory support for advanced preclinical testing platforms.
Which sectors in Canada are adopting PDX models?
In Canada, PDX models are being adopted by academic medical centers, contract research organizations, pharmaceutical companies, and biotechnology firms focused on oncology and personalized medicine.
How does Canada's PDX market compare to North America?
Canada represents a significant portion of the North American PDX market, with strong research capabilities and healthcare innovation driving steady growth aligned with regional trends.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report